Journal of Endocrinological Investigation

, Volume 23, Issue 4, pp 258–262 | Cite as

Lack of reduction in body fat after treatment with insulin-like growth factor-I in two children with growth hormone gene deletions

  • I. J. P. Arnhold
  • S. B. Oliveira
  • M. G. F. Osorio
  • A. J. F. Carrilho
  • W. Nicolau
  • A. C. Bianco
  • B. B. Mendonca
Case Report


Two patients with growth hormone (GH) gene deletions were treated with recombinant insulin-like growth factor-I (IGF-I) (80–240 (μg/kg/ day) and the effects on bone mass and body composition were compared to administration of GH (0.075 U/kg/day) to 8 patients with idiopathic GH deficiency. Bone mass and body composition were measured by dual photon X-ray absorptiometry (DEXA) before and 3 and 6 months after treatment with GH or IGF-I. Similar increases in growth velocities were observed after GH and IGF-I treatment. Treatment with GH resulted in prompt and significant reduction in body fat percentage (basal, 3 and 6 months: 22±10, 17±9, and 16±9%) whereas body fat percentage remained unchanged after IGF-I therapy (basal, 3 and 6 months: 49, 52 and 48% in patient 1 and 45, 42 and 43% in patient 2, respectively). Fat percentage remained elevated after 18 months of IGF-I treatment in patients 1 (51%) and 2 (44%), respectively. Lean mass and bone mineral content increased with GH and IGF-I therapies. We conclude that reduction of body fat measured by DEXA, observed after administration of GH but not after IGF-I treatment in these children with GH deficiency, suggests that the GH effect on body fat mass is not mediated by circulating IGF-I.


IGF-I treatment body composition GH deficiency GH gene deletions body fat 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Richelsen B. Action of growth hormone in adipose tissue. Horm. Res. 1997, 48 (Suppl. 5): 105–110.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285–288.PubMedCrossRefGoogle Scholar
  3. 3.
    Boot A.M., Engels M.A.M.J., Boerma G.J.M., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 2423–2428.PubMedGoogle Scholar
  4. 4.
    Degerblad M., Elgingy N., Hall K., Sjöberg H.E., Thoren M. Potent effect of recombinant human growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocr. (Copenh) 1992, 126: 387–393.Google Scholar
  5. 5.
    Laron Z., Klinger B. Body fat in Laron syndrome patients: effect of insulinlike growth factor I treatment. Horm. Res. 1993, 40: 16–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Guevara-Aguirre J., Rosenbloom A.L., Vasconez O., Martinez V., Gargosky S.E., Allen L., Rosenfeld R.G. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: Comparison of two dosage levels and to GH-treated GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 629–633.PubMedGoogle Scholar
  7. 7.
    Underwood L.E., Backeljauw P., Duncan V., GHIS Collaborative Group. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr. Scand. 1999, Suppl. 428: 182–184.CrossRefGoogle Scholar
  8. 8.
    Kamijo T., Phillips J.A. III Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. J. Clin. Endocrinol. Metab. 1992, 74: 786–789.PubMedCrossRefGoogle Scholar
  9. 9.
    Arnhold I.J.P., Oliveira S.B., Osorio M.G.F., Mendonca B.B. Insulin-like growth factor-I treatment in two children with growth hormone gene deletions. J. Pediatr. Endocrinol. Metab. 1999, 12: 499–506.PubMedCrossRefGoogle Scholar
  10. 10.
    Boot A.M., Bouquet J., de Ridder M.A.J., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Determinants of body composition measured by dualenergy X-ray absorptiometry in Dutch children and adolescents. Am. J. Clin. Nutr. 1997, 66: 232–238.PubMedGoogle Scholar
  11. 11.
    Carrilho A.J.F., Medina W.L., Nakandakare E.R., Quintão E.C.R. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 1997, 62: 82–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Osorio M.G.F., Bianco A.C., Estefan V., Segura T.C., Arnhold I.J.P., Nicolau W., Mendonca B.B. Body composition and bone mass of children with hypopituitarism following six months of human growth hormone therapy. Arq. Bras. Endocrinol. Metabol. 1998, 42: 357–362.Google Scholar
  13. 13.
    Ranke M.B., Savage M.O., Chatelain P.G., Preece M.A., Rosenfeld R.G., Blum M.F., Wilton P. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years results. Horm. Res. 1995, 44: 253–264.PubMedCrossRefGoogle Scholar
  14. 14.
    Backeljauw P.F., Underwood L.E., GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 3312–3317.PubMedGoogle Scholar
  15. 15.
    Klinger B., Laron Z. Three year treatment of children with Laron syndrome. J. Pediatr. Endocrinol. Metab. 1995, 8: 149–158.PubMedCrossRefGoogle Scholar
  16. 16.
    Woods K.A., Camacho-Hübner C., Savage M.O., Clark A.J.L. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New Engl. J. Med. 1996, 335: 1363–1367.PubMedCrossRefGoogle Scholar
  17. 17.
    Heinrichs C., Vis H.L., Bergmann P., Wilton P., Bourguignon J.P. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin. Endocrinol. 1993, 38: 647–651.CrossRefGoogle Scholar
  18. 18.
    Rudling M., Olivecrona H., Eggertsen G., Angelin B. Regulation of rat hepatic low density lipoprotein receptors–in vivo stimulation by growth hormone is not mediated by insulin-like growth factor I. J. Clin. Invest. 1996, 97: 292–299.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J.-A., Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA. 1992, 89: 6983–6987.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2000

Authors and Affiliations

  • I. J. P. Arnhold
    • 1
  • S. B. Oliveira
    • 1
  • M. G. F. Osorio
    • 1
  • A. J. F. Carrilho
    • 2
  • W. Nicolau
    • 1
  • A. C. Bianco
    • 3
  • B. B. Mendonca
    • 1
  1. 1.Unidade de Endocrinologia do DesenvolvimentoHospital das Clinicas da Faculdade de Medicina da USPSão PauloBrazil
  2. 2.Laboratório de Lípides, Divisão de EndocrinologiaHospital das Clinicas da Faculdade de Medicina da USPSão PauloBrazil
  3. 3.Departmento de Fisiologia e Biofísica, ICBUniversidade de São PauloSão PauloBrazil

Personalised recommendations